"Pharmaceutical Speed Reader" mRNA vaccine start phase 3 clinical multi-drug recommended by the European Union approval.

July 28, 2020 / Medical Information List: Moderna New Crown Vaccine Launches Phase 3 Clinical; Lingke Pharmaceuticals Has Been Granted the Development of New RAS Inhibitors; Keytruda's Sixth Listing Application in China is to be included in the Priority Review; AstraZeneca Calquence has been approved by the European Union for the treatment of adult Patients with CLL... Daily fresh medicine to hear medical news, fast-reading society with you to pay attention! Part 1 Policy Brief July 27 National new confirmed local cases July 27 0-24, 31 provinces (autonomous regions, municipalities directly under the Central Government) and Xinjiang Production and Construction Corps reported 68 new confirmed cases, of which 4 cases imported from abroad (Shanghai 2 cases, Beijing 1, Yunnan 1), 64 cases (57 cases in Xinjiang, 6 cases in Liaoning, 1 in Beijing);
(National Health and Health Commission) Guizhou Province took the lead in the introduction of test-free village medical landing policy recently, Guizhou Provincial Health and Health Commission Grassroots Health Department issued "on Guizhou Province to allow medical professional college graduates to apply for the registration of rural doctors without examination notice", the launch of "Guizhou Province rural doctors thousands of people needs plan."
it is understood that Guizhou, as one of the 16 regions implementing the test-free policy, took the lead in throwing an olive branch to local medical college graduates to transport the new force son of primary care in rural areas.
(Provincial Health and Health Commission Primary Health Department) Part 2 Production and Observation Lingke Pharmaceuticals was authorized to develop new RAS inhibitors on the 27th, Lingke Pharmaceuticals announced an exclusive authorization agreement with Kobe University and the Japan Institute of Science and Chemistry to develop RAS inhibitors with a new drug action mechanism.
also, the agreement between Lingke Pharmaceuticals and Kobe University also includes continued technical support for active screening and structure sedits by Kobe University.
(Pharmaceutical Mission) Part 3 Pharmaceutical Information Moderna New Crown Vaccine Launch Phase 3 Clinical 27, Moderna announced that the company developed the mRNA vaccine for the new coronavirus phase 3 research has begun to administer to participants.
Phase 3 of the study, known as THE COVE Study, in collaboration with the National Institutes of Allergy and Infectious Diseases, part of the National Institutes of Health, and the Biomedical Advanced Research and Development Administration.
(immediate drug news) Run new biology class 1 new drug completed the second phase of clinical first clinical patient-to-drug new biology announced that it is in the research of the new drug RX108 treatment of recurrent metastatic head and neck symour phase 2 clinical study recently completed the first patient administration at Shanghai Oriental Hospital.
RX108 is a global intellectual property innovation of Runxin Bio independent research and development, is a novel Na-K-ATP enzyme inhibitor, with a "one-goal multi-point" mechanism, can play an anti-tumor role through a variety of ways.
(Pharmaceutical Mission) Haizheng Pharmaceuticals "Acapo Sugar Tablet" approved Haizheng Pharmaceuticals issued a notice that recently, the company received the State Drug Administration approved the issuance of Acapo sugar tablets "drug registration approval."
acapo saccharine tablets are suitable for the treatment of type 2 diabetes, as well as to reduce post-meal blood sugar in people with low sugar tolerance.
(Haizheng PharmaceuticalS Announcement) Keytruda's sixth listing application in China is to be included in the latest public announcement of priority review CDE, and the application for listing of a new drug in Keytruda, a heavy PD-1 inhibitor developed by Mercadon, is to be included in the priority review, and the reasons for inclusion are subject to conditional approval.
This is Keytruda's sixth listing application in China, according to CDE's website, and from the progress of clinical trials and industry dynamics being conducted in China, indications may be a front-line treatment for advanced hepatocellular carcinoma.
previously approved five indications in China for melanoma, non-small cell lung cancer, etc.
(CDE) Huahai Pharmaceutical Sachlorate tablets approved by the U.S. FDA, the number of Huahai Pharmaceuticals issued a notice, recently received the U.S. FDA notice, the company to the FDA to declare the new drug application for the acetate tablets has been approved.
hydrochloride tablets are mainly used to treat minor brain dysfunction attention deficit disorder, etc.
(Huahai Pharmaceutical SC Announcement) The world's first Inphyxitic sC form was approved for five new indications, Celltrion announced that the European Commission has approved Remsima (Inphyxi, CT-P13) subcutaneous (SC) preparations for intravenous preparation of all previously approved adult indications, including: strong direct scoliosis, Crohn's disease, ulcerative colitis, psoriasis, psoriasis.
(Sina Pharmaceutical News) Imfinzi joint chemotherapy first-line treatment of widespread small cell lung cancer was recommended by CHMP on the 27th, AstraZeneca announced that Imfinzi joint lysinposide and cappelin or cisplatin for the first-line treatment of adult wide-ranging small cell lung cancer to obtain the European Medicines Agency (EMA) Human Use Medicines Committee (CHMP) recommended for sale in the European Union.
(Sina Pharmaceutical News) AstraZeneca Calquence has been approved by the European Union for the treatment of adult patients with CLL, a society has announced that the European Medicines Agency (EMA) Human Pharmaceutical Products Committee (CHMP) has issued a positive review, recommending the approval of Calquence for the treatment of chronic lymphocytic leukemia (CLL) adult patients.
now, CHMP's positive comments will be reviewed by the European Commission, which is expected to make a final review decision within the next two months.
(Bio Valley) new non-opioid painkiller Zynrelef was approved by the European Union CHMP, Heron announced that the European Medicines Agency (EMA) Human Pharmaceutical Products Board (CHMP) has issued a positive review recommending the approval of Zynrelef, a non-opioid painkiller in the study, for the management of postoperative pain.
now, CHMP's positive comments will be reviewed by the European Commission, which is expected to make a final review decision in September 2020.
(Biovalley) Concord Iho-Crysvita Treatment X-Chain Low Phosphiemia Treatment X-Chain Low Phosphatism Was recommended by the European Union, the Association and Kirin announced that the European Medicines Agency (EMA) Human Pharmaceutical Products Committee (CHMP) has issued a positive review, recommending that Crysvita be extended to include X-chain hypophoscopy adolescents and adult patients.
now, CHMP's positive comments will be reviewed by the European Commission, which is expected to make a final review decision in September 2020.
(Biovalley) the first bird-type mycobacteria-induced non-tuberculosis tuberculosis lung disease drug Arikayce EU will be approved in The European Union recently announced that the European Medicines Agency (EMA) Human Pharmaceutical Products Committee (CHMP) has issued a positive review, recommending the approval of Arikayce, for the treatment of adult patients with limited selection of cystic fibrosis, treatment of non-TB mycobacteria infection caused by ocobacteria.
now, CHMP's positive comments will be reviewed by the European Commission, which is expected to make a final review decision in the second half of the year.
(Bio Valley)